DOCSLIB.ORG

Gene Names Given for Individuals with Available DNA Sample § Represent Schizophrenia Affected Individuals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gene Names Given for Individuals with Available DNA Sample § Represent Schizophrenia Affected Individuals Supplementary Figure 1 : Pedigree of families used for whole exome sequencing Showing prioritized variants encompassing genes and their transmission § Gene names given for individuals with available DNA sample § represent schizophrenia affected individuals § Un affected individuals § Circles and rectangles filled with other colors represent other forms of psychiatric disorders § Representing samples used for WES § # Representing the samples used for target capture sequencing Figure 1a : Family1 I I.1 I.2 I.3 I.4 II.1 II.2 II.3 II.4 II.5 II.6 # II.7 # II.8 II.9 II.10 II.11 II ADAMTS3 SETDB1 LRRTM2 LRP2 TIAM2 TTC21B UNC13B GRIN3A SHANK2 AKAP5 PRODH FLNA III III.1 III.2 III.3 III.4 III.5 ADAMTS3 ADAMTS3 ADAMTS3 LRRTM2 LRRTM2 LRRTM2 TIAM2 TIAM2 TIAM2 UNC13B UNC13B UNC13B SHANK2 SHANK2 SHANK2 Dissociative disorder PRODH PRODH PRODH SETDB1 SETDB1 SETDB1 Psychosis LRP2 LRP2 LRP2 TTC21B TTC21B TTC21B GRIN3A GRIN3A GRIN3A AKAP5 AKAP5 AKAP5 FLNA FLNA FLNA Figure 1b : Family 2 I.1 I.2 I.3 I.4 I II II.1 # II.2 # II.3 II.4 II.5 II.6 II.7 CASR GABRR3 MAGI2 DOCK3 GLI3 PDE8B CALHM1 VPS13B INA CACNG7 PLAUR III III.1 III.2 III.3 III.4 # III.5 # III.6 # III.7# III.8 # DOCK3 GABRR3 CALHM1 GABRR3 GABRR3 PDE8B DOCK3 INA DOCK3 DOCK3 VPS13B PDE8B PLAUR PDE8B PDE8B CACNG7 VPS13B VPS13B VPS13B CACNG7 CACNG7 CACNG7 CASR CASR CASR MAGI2 MAGI2 MAGI2 Psychosis GLI3 GLI3 GLI3 Dissociative disorder CALHM1 CALHM1 CALHM1 INA INA INA PLAUR PLAUR PLAUR Figure 1c: Family 3 I I.3 I.4 I.1 I.2 II II.1 II.2 II.3 # II.4 II.5 II.6 KIRREL SCN11A UBA6 III III.1 III.2 III.3 III.4 # III.5 # III.6 III.7 III.8 GBX2 GBX2 GBX2 GBX2 CELSR3 MINK1 CELSR3 CELSR3 CDCA7L SCN11A CDCA7L CDCA7L MINK1 UBA6 MINK1 MINK1 NTN1 NTN1 NTN1 KIRREL KIRREL KIRREL SCN11A SCN11A SCN11A UBA6 UBA6 UBA6 IV IV.1 # IV.2 IV.3 IV.4 GBX2 MINK1 SCN11A UBA6 Figure 1d: Family 4 I I.1 I.2 I.3 I.4 II II.8 # II.9 II.10 II.11 II.12 II.13 II.1 II.2 II.3 II.4 II.5 II.6 II.7 # LRRC7 KIF1A KIF1A SCN10A CCKAR FZD9 SYT12 SMARCC2 GNB1L PQBP1 III III.1 III.2 III.3 III.4 III.5 III.6 III.7 LRRC7 LRRC7 LRRC7 KIF1A KIF1A KIF1A KIF1A KIF1A KIF1A SCN10A SCN10A SCN10A CCKAR CCKAR CCKAR FZD9 FZD9 FZD9 SYT12 SYT12 SYT12 SMARCC2 SMARCC2 SMARCC2 GNB1L GNB1L GNB1L PQBP1 PQBP1 PQBP1 Figure 1e: Family 5 I I.1 I.2 I.3 I.4 II II.5 # II.9 II.1 II.2 II.3 II.4 # II.6 II.7 II.8 KDM4A DLG1 NOTCH2 ABHD6 TRPA1 WASF1 PLCB3 HTR3A RIC8A PLCB3 ARPC3 TSC2 ACTN1 CACNG4 III III.1 III.2 III.3 III.4 III.5 KDM4A KDM4A KDM4A NOTCH2 NOTCH2 NOTCH2 PLCB3 TRPA1 TRPA1 ACTN1 PLCB3 PLCB3 ABHD6 RIC8A RIC8A Psychiatric illness ARPC3 ARPC3 PLCB3 Bipolar disorder CACNG4 ACTN1 ACTN1 DLG1 DLG1 ABHD6 ABHD6 WASF1 WASF1 HTR3A HTR3A PLCB3 PLCB3 TSC2 TSC2 CACNG4 CACNG4 Figure 1f: Family 6 I I.1 I.2 II II.1 # II.2 # II.3 II.4 II.5 II.6 IQSEC1 INPP4A LIN7C KIF5C CHRM4 NSUN2 PRRT2 SFRP1 RAI1 TNC ABL1 PAX6 LRP4 III III.1 III.1 III.1 III.4 III.5 III.6 III.7 III.8 ASCL1 ASCL1 ASCL1 INPP4A INPP4A INPP4A KIF5C KIF5C KIF5C NSUN2 NSUN2 NSUN2 SFRP1 SFRP1 SFRP1 TNC TNC TNC ABL1 ABL1 ABL1 PAX6 PAX6 PAX6 LRP4 LRP4 LRP4 IQSEC1 IQSEC1 IQSEC1 LIN7C LIN7C LIN7C CHRM4 CHRM4 CHRM4 PRRT2 PRRT2 PRRT2 RAI1 RAI1 RAI1 Figure 1g: Family 7 I I.1 I.2 I.3 I.4 II II.1 II.2 II.3 # II.4 # II.5 II.6 II.7 II.8 AGRN DISC1 SLC25A12 PTPRN WNT2 PTPRD PCDH9 PLCB3 TRPV3 DYNC1H1 BSG PNPO III III.1 # III.2 III.3 III.4 III.5 III.6 III.7 AGRN AGRN AGRN SLC25A12 SLC25A12 SLC25A12 WNT2 WNT2 WNT2 PCDH9 PCDH9 PCDH9 TRPV3 TRPV3 TRPV3 BSG BSG BSG DISC1 DISC1 DISC1 PTPRN PTPRN PTPRN PTPRD PTPRD PTPRD PLCB3 PLCB3 PLCB3 DYNC1H1 DYNC1H1 DYNC1H1 PNPO PNPO PNPO Figure 1h: Family 8 I I.1 I.2 I.3 I.4 II II.8 II.9 II.1 II.2 II.3 II.4 II.5 II.6 # II.7 # II.10 II.11 II.12 PTPN4 EIF2AK3 KIF20B INPP4A ANK3 TRAK1 GRIN3B EGF TBX1 MPDZ PRRT2 III III.1 III.2 III.3 III.4 III.5 PTPN4 PTPN4 PTPN4 KIF20B KIF20B KIF20B ANK3 ANK3 ANK3 GRIN3B GRIN3B GRIN3B TBX1 TBX1 TBX1 EIF2AK3 EIF2AK3 EIF2AK3 INPP4A INPP4A INPP4A TRAK1 TRAK1 TRAK1 EGF EGF EGF MPDZ MPDZ MPDZ PRRT2 PRRT2 PRRT2 Figure 1i: Family 9 I I.1 I.2 I.3 I.4 II II.1 # II.2 # II.3 II.4 II.5 II.6 SCN2A SCN2A GTF2IRD1 KALRN LAMA1 CLSTN2 LMTK3 DRD3 L3MBTL1 PDGFRB GPR151 KCNT1 III III.1 III.2 III.3 III.4 III.5 SCN2A SCN2A SCN2A GTF2IRD1 GTF2IRD1 GTF2IRD1 LAMA1 LAMA1 LAMA1 LMTK3 LMTK3 LMTK3 L3MBTL1 L3MBTL1 L3MBTL1 SCN2A SCN2A SCN2A KALRN KALRN KALRN CLSTN2 CLSTN2 CLSTN2 DRD3 DRD3 DRD3 PDGFRB PDGFRB PDGFRB GPR151 GPR151 GPR151 KCNT1 KCNT1 KCNT1 Figure 1j: Family 10 I I.1 I.2 I.3 I.4 II II.1 II.2 II.3 II.4 # II.5 II.6 II.7 II.8 PLXNA2 PLD1 TH IQSEC3 THBS1 LAMA1 EFNA2 III III.1 # III.2 III.3 III.4 III.5 # III.6 III.7 PCM1 GRM7 GRM7 GRM7 GRM2 SHANK3 NEURL1 GRM2 GRM2 PCM1 PLD1 LAMA1 PCM1 PCM1 NRP1 IQSEC3 NRP1 NRP1 PTPRT Psychotic disorder THBS1 NEURL1 NEURL1 SHANK3 LAMA1 PTPRT PTPRT PLXNA2 EFNA2 SHANK3 SHANK3 PLD1 PLXNA3 PLXNA3 TH PLXNA2 PLXNA2 IQSEC3 PLD1 PLD1 LAMA1 TH TH EFNA2 IQSEC3 IQSEC3 THBS1 THBS1 LAMA1 LAMA1 EFNA2 EFNA2 Figure 1k: Family 11 I I.1 I.2 I.3 I.4 II II.8 II.9 II.1 II.2 II.3 II.4 II.5 II.6 # II.7 # II.10 II.11 II.12 ANK2 KMT2E FGF23 GRIN3B ARR3 III III.1 III.2 # III.3 III.4 III.5 ANK2 ANK2 KMT2E KMT2E FGF23 FGF23 GRIN3B GRIN3B ARR3 ARR3.
Load more

Recommended publications
  • KIF1A-Related Autosomal Dominant Spastic Paraplegias (SPG30) in Russian Families G
    Rudenskaya et al. BMC Neurology (2020) 20:290 https://doi.org/10.1186/s12883-020-01872-4 RESEARCH ARTICLE Open Access KIF1A-related autosomal dominant spastic paraplegias (SPG30) in Russian families G. E. Rudenskaya1 , V. A. Kadnikova1* , O. P. Ryzhkova1 , L. A. Bessonova1, E. L. Dadali1 , D. S. Guseva1 , T. V. Markova1 , D. N. Khmelkova2 and A. V. Polyakov1 Abstract Background: Spastic paraplegia type 30 (SPG30) caused by KIF1A mutations was first reported in 2011 and was initially considered a very rare autosomal recessive (AR) form. In the last years, thanks to the development of massive parallel sequencing, SPG30 proved to be a rather common autosomal dominant (AD) form of familial or sporadic spastic paraplegia (SPG),, with a wide range of phenotypes: pure and complicated. The aim of our study is to detect AD SPG30 cases and to examine their molecular and clinical characteristics for the first time in the Russian population. Methods: Clinical, genealogical and molecular methods were used. Molecular methods included massive parallel sequencing (MPS) of custom panel ‘spastic paraplegias’ with 62 target genes complemented by familial Sanger sequencing. One case was detected by the whole -exome sequencing. Results: AD SPG30 was detected in 10 unrelated families, making it the 3rd (8.4%) most common SPG form in the cohort of 118 families. No AR SPG30 cases were detected. In total, 9 heterozygous KIF1A mutations were detected, with 4 novel and 5 known mutations. All the mutations were located within KIF1A motor domain. Six cases had pure phenotypes, of which 5 were familial, where 2 familial cases demonstrated incomplete penetrance, early onset and slow relatively benign SPG course.
    [Show full text]
  • Dimerization of Mammalian Kinesin-3 Motors Results in Superprocessive Motion
    Dimerization of mammalian kinesin-3 motors results in superprocessive motion Virupakshi Soppinaa,1, Stephen R. Norrisa,b, Aslan S. Dizajia, Matt Kortusa, Sarah Veatchb, Michelle Peckhamc, and Kristen J. Verheya,1 aDepartment of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109; bDepartment of Biophysics, University of Michigan, Ann Arbor, MI 48109; and cSchool of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom Edited by J. Richard McIntosh, University of Colorado, Boulder, CO, and approved March 7, 2014 (received for review January 15, 2014) The kinesin-3 family is one of the largest among the kinesin Defects in kinesin-3 transport have been implicated in a wide superfamily and its members play important roles in a wide range variety of neurodegenerative, developmental, and cancer dis- of cellular transport activities, yet the molecular mechanisms of eases (22). However, a mechanistic understanding of this im- kinesin-3 regulation and cargo transport are largely unknown. portant class of cellular transporters is currently limited. We performed a comprehensive analysis of mammalian kinesin-3 To date, mechanistic studies have focused on truncated ver- motors from three different subfamilies (KIF1, KIF13, and KIF16). sions of mammalian KIF1A and its homolog CeUNC-104, and Using Forster resonance energy transfer microscopy in live cells, these studies have yielded contradictory results (23). For exam- we show for the first time to our knowledge that KIF16B motors ple, murine KIF1A has been proposed to function as a monomer undergo cargo-mediated dimerization. The molecular mechanisms that diffuses along the microtubule surface or as a processive dimer.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Natural Variants in C. Elegans Atg-5 3'UTR Uncover Divergent Effects of Autophagy on Polyglutamine Aggregation in Different Tissues
    bioRxiv preprint doi: https://doi.org/10.1101/670042; this version posted June 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Natural variants in C. elegans atg-5 3'UTR uncover divergent effects of autophagy on polyglutamine aggregation in different tissues Alexander-Floyd J1, Haroon S2, Ying M1, Entezari AA1,3, Jaeger C1,4, Vermulst M2,5, Gidalevitz T1,#. 1 Biology Department, Drexel University, Philadelphia, PA 19104 2 Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA 19104 3Current address: Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107 4Current address: Department of Neuroradiology, Technical University of Munich, Munich, Germany TUM-Neuroimaging Center, Technical University of Munich, Munich, Germany 5Current address: Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA 90089 # Corresponding author. Address correspondence to T.G. ([email protected]) Short title: Divergent effects of autophagy on polyglutamine aggregation in different tissues bioRxiv preprint doi: https://doi.org/10.1101/670042; this version posted June 13, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Diseases caused by protein misfolding and aggregation, in addition to cell selectivity, often exhibit variation among individuals in the age of onset, progression, and severity of disease.
    [Show full text]
  • Full Disclosure Forms
    Expanding genotype/phenotype of neuromuscular diseases by comprehensive target capture/NGS Xia Tian, PhD* ABSTRACT * Wen-Chen Liang, MD Objective: To establish and evaluate the effectiveness of a comprehensive next-generation * Yanming Feng, PhD sequencing (NGS) approach to simultaneously analyze all genes known to be responsible for Jing Wang, MD the most clinically and genetically heterogeneous neuromuscular diseases (NMDs) involving spi- Victor Wei Zhang, PhD nal motoneurons, neuromuscular junctions, nerves, and muscles. Chih-Hung Chou, MS Methods: All coding exons and at least 20 bp of flanking intronic sequences of 236 genes causing Hsien-Da Huang, PhD NMDs were enriched by using SeqCap EZ solution-based capture and enrichment method fol- Ching Wan Lam, PhD lowed by massively parallel sequencing on Illumina HiSeq2000. Ya-Yun Hsu, PhD ; 3 Thy-Sheng Lin, MD Results: The target gene capture/deep sequencing provides an average coverage of 1,000 per Wan-Tzu Chen, MS nucleotide. Thirty-five unrelated NMD families (38 patients) with clinical and/or muscle pathologic Lee-Jun Wong, PhD diagnoses but without identified causative genetic defects were analyzed. Deleterious mutations Yuh-Jyh Jong, MD were found in 29 families (83%). Definitive causative mutations were identified in 21 families (60%) and likely diagnoses were established in 8 families (23%). Six families were left without diagnosis due to uncertainty in phenotype/genotype correlation and/or unidentified causative Correspondence to genes. Using this comprehensive panel, we not only identified mutations in expected genes but Dr. Wong: also expanded phenotype/genotype among different subcategories of NMDs. [email protected] or Dr. Jong: Conclusions: Target gene capture/deep sequencing approach can greatly improve the genetic [email protected] diagnosis of NMDs.
    [Show full text]
  • Biological Models of Colorectal Cancer Metastasis and Tumor Suppression
    BIOLOGICAL MODELS OF COLORECTAL CANCER METASTASIS AND TUMOR SUPPRESSION PROVIDE MECHANISTIC INSIGHTS TO GUIDE PERSONALIZED CARE OF THE COLORECTAL CANCER PATIENT By Jesse Joshua Smith Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University In partial fulfillment of the requirements For the degree of DOCTOR OF PHILOSOPHY In Cell and Developmental Biology May, 2010 Nashville, Tennessee Approved: Professor R. Daniel Beauchamp Professor Robert J. Coffey Professor Mark deCaestecker Professor Ethan Lee Professor Steven K. Hanks Copyright 2010 by Jesse Joshua Smith All Rights Reserved To my grandparents, Gladys and A.L. Lyth and Juanda Ruth and J.E. Smith, fully supportive and never in doubt. To my amazing and enduring parents, Rebecca Lyth and Jesse E. Smith, Jr., always there for me. .my sure foundation. To Jeannine, Bill and Reagan for encouragement, patience, love, trust and a solid backing. To Granny George and Shawn for loving support and care. And To my beautiful wife, Kelly, My heart, soul and great love, Infinitely supportive, patient and graceful. ii ACKNOWLEDGEMENTS This work would not have been possible without the financial support of the Vanderbilt Medical Scientist Training Program through the Clinical and Translational Science Award (Clinical Investigator Track), the Society of University Surgeons-Ethicon Scholarship Fund and the Surgical Oncology T32 grant and the Vanderbilt Medical Center Section of Surgical Sciences and the Department of Surgical Oncology. I am especially indebted to Drs. R. Daniel Beauchamp, Chairman of the Section of Surgical Sciences, Dr. James R. Goldenring, Vice Chairman of Research of the Department of Surgery, Dr. Naji N.
    [Show full text]
  • An Integrated Approach to Comprehensively Map the Molecular Context of Proteins
    bioRxiv preprint doi: https://doi.org/10.1101/264788; this version posted February 13, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Liu et al. An integrated approach to comprehensively map the molecular context of proteins Xiaonan Liu1,2, Kari Salokas1,2, Fitsum Tamene1,2,3 and Markku Varjosalo1,2,3* 1Institute of Biotechnology, University of Helsinki, Helsinki 00014, Finland 2Helsinki Institute of Life Science, University of Helsinki, Helsinki 00014, Finland 3Proteomics Unit, University of Helsinki, Helsinki 00014, Finland *Corresponding author Abstract: Protein-protein interactions underlie almost all cellular functions. The comprehensive mapping of these complex cellular networks of stable and transient associations has been made available by affi nity purifi cation mass spectrometry (AP-MS) and more recently by proximity based labelling methods such as BioID. Due the advancements in both methods and MS instrumentation, an in-depth analysis of the whole human proteome is at grasps. In order to facilitate this, we designed and optimized an integrated approach utilizing MAC-tag combining both AP-MS and BioID in a single construct. We systematically applied this approach to 18 subcellular localization markers and generated a molecular context database, which can be used to defi ne molecular locations for any protein of interest. In addition, we show that by combining the AP-MS and BioID results we can also obtain interaction distances within a complex. Taken together, our combined strategy off ers comprehensive approach for mapping physical and functional protein interactions. Introduction: Majority of proteins do not function in isolation geting the endogenous bait protein, allowing and their interactions with other proteins defi ne purifi cation of the bait protein together with the their cellular functions.
    [Show full text]
  • The Kinesin Superfamily Handbook Transporter, Creator, Destroyer
    The Kinesin Superfamily Handbook Transporter, Creator, Destroyer Edited by Claire T. Friel First edition published 2020 ISBN: 978-1-138-58956-8 (hbk) ISBN: 978-0-429-49155-9 (ebk) 4 The Kinesin-3 Family Long-Distance Transporters Nida Siddiqui and Anne Straube CC BY-NC-ND 4.0 The Kinesin Superfamily Handbook The Kinesin-3 Family 4 Long-Distance Transporters Nida Siddiqui and Anne Straube CONTENTS 4.1 Example Family Members .............................................................................. 41 4.2 Structural Information .................................................................................... 41 4.3 Functional Properties ...................................................................................... 43 4.3.1 Autoinhibition of Kinesin-3 Motors and Their Activation .................45 4.4 Physiological Roles .........................................................................................46 4.4.1 Preference for Subsets of Microtubule Tracks .................................... 47 4.5 Involvement in Disease ...................................................................................48 Acknowledgements ..................................................................................................49 References ................................................................................................................49 The Kinesin-3s are a family of cargo transporters. They typically display highly processive plus-end-directed motion, either as dimers or in teams, formed via interaction with
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Effector Gene Expression Potential to Th17 Cells by Promoting Microrna
    Downloaded from http://www.jimmunol.org/ by guest on September 26, 2021 is online at: average * The Journal of Immunology published online 17 May 2013 from submission to initial decision 4 weeks from acceptance to publication http://www.jimmunol.org/content/early/2013/05/17/jimmun ol.1300351 MicroRNA-155 Confers Encephalogenic Potential to Th17 Cells by Promoting Effector Gene Expression Ruozhen Hu, Thomas B. Huffaker, Dominique A. Kagele, Marah C. Runtsch, Erin Bake, Aadel A. Chaudhuri, June L. Round and Ryan M. O'Connell J Immunol Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/suppl/2013/05/17/jimmunol.130035 1.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 26, 2021. Published May 17, 2013, doi:10.4049/jimmunol.1300351 The Journal of Immunology MicroRNA-155 Confers Encephalogenic Potential to Th17 Cells by Promoting Effector Gene Expression Ruozhen Hu,* Thomas B. Huffaker,* Dominique A. Kagele,* Marah C. Runtsch,* Erin Bake,* Aadel A. Chaudhuri,† June L.
    [Show full text]
  • 1 Fibrillar Αβ Triggers Microglial Proteome Alterations and Dysfunction in Alzheimer Mouse 1 Models 2 3 4 Laura Sebastian
    bioRxiv preprint doi: https://doi.org/10.1101/861146; this version posted December 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Fibrillar triggers microglial proteome alterations and dysfunction in Alzheimer mouse 2 models 3 4 5 Laura Sebastian Monasor1,10*, Stephan A. Müller1*, Alessio Colombo1, Jasmin König1,2, Stefan 6 Roth3, Arthur Liesz3,4, Anna Berghofer5, Takashi Saito6,7, Takaomi C. Saido6, Jochen Herms1,4,8, 7 Michael Willem9, Christian Haass1,4,9, Stefan F. Lichtenthaler 1,4,5# & Sabina Tahirovic1# 8 9 1 German Center for Neurodegenerative Diseases (DZNE) Munich, 81377 Munich, Germany 10 2 Faculty of Chemistry, Technical University of Munich, Garching, Germany 11 3 Institute for Stroke and Dementia Research (ISD), Ludwig-Maximilians Universität München, 12 81377 Munich, Germany 13 4 Munich Cluster for Systems Neurology (SyNergy), Munich, Germany 14 5 Neuroproteomics, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, 15 Munich, Germany 16 6 Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Institute, Wako, 17 Saitama 351-0198, Japan 18 7 Department of Neurocognitive Science, Nagoya City University Graduate School of Medical 19 Science, Nagoya, Aichi 467-8601, Japan 20 8 Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität München, 81377 21 Munich, Germany 22 9 Biomedical Center (BMC), Ludwig-Maximilians Universität München, 81377 Munich, Germany 23 10 Graduate School of Systemic Neuroscience, Ludwig-Maximilians-University Munich, Munich, 24 Germany. 25 *Contributed equally 26 #Correspondence: [email protected] and [email protected] 27 28 Running title: 29 Microglial proteomic signatures of AD 30 Keywords: Alzheimer’s disease / microglia / proteomic signatures / neuroinflammation / 31 phagocytosis 32 1 bioRxiv preprint doi: https://doi.org/10.1101/861146; this version posted December 2, 2019.
    [Show full text]
  • A Genomic Approach to Delineating the Occurrence of Scoliosis in Arthrogryposis Multiplex Congenita
    G C A T T A C G G C A T genes Article A Genomic Approach to Delineating the Occurrence of Scoliosis in Arthrogryposis Multiplex Congenita Xenia Latypova 1, Stefan Giovanni Creadore 2, Noémi Dahan-Oliel 3,4, Anxhela Gjyshi Gustafson 2, Steven Wei-Hung Hwang 5, Tanya Bedard 6, Kamran Shazand 2, Harold J. P. van Bosse 5 , Philip F. Giampietro 7,* and Klaus Dieterich 8,* 1 Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, 38000 Grenoble, France; [email protected] 2 Shriners Hospitals for Children Headquarters, Tampa, FL 33607, USA; [email protected] (S.G.C.); [email protected] (A.G.G.); [email protected] (K.S.) 3 Shriners Hospitals for Children, Montreal, QC H4A 0A9, Canada; [email protected] 4 School of Physical & Occupational Therapy, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada 5 Shriners Hospitals for Children, Philadelphia, PA 19140, USA; [email protected] (S.W.-H.H.); [email protected] (H.J.P.v.B.) 6 Alberta Congenital Anomalies Surveillance System, Alberta Health Services, Edmonton, AB T5J 3E4, Canada; [email protected] 7 Department of Pediatrics, University of Illinois-Chicago, Chicago, IL 60607, USA 8 Institut of Advanced Biosciences, Université Grenoble Alpes, Inserm, U1209, CHU Grenoble Alpes, 38000 Grenoble, France * Correspondence: [email protected] (P.F.G.); [email protected] (K.D.) Citation: Latypova, X.; Creadore, S.G.; Dahan-Oliel, N.; Gustafson, Abstract: Arthrogryposis multiplex congenita (AMC) describes a group of conditions characterized A.G.; Wei-Hung Hwang, S.; Bedard, by the presence of non-progressive congenital contractures in multiple body areas.
    [Show full text]